Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia

BACKGROUND: Fludarabine, cyclophosphamide and rituximab (FCR) results in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports suggest that in patients with relapsed CLL a dose-intensified rituximab regimen increases response rates compared to s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Short, Nicholas J., Keating, Michael J., Wierda, William G., Faderl, Stefan, Ferrajoli, Alessandra, Estrov, Zeev, Smith, Susan C., O'Brien, Susan M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824541/
https://ncbi.nlm.nih.gov/pubmed/26218678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29605
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars